Viridian Therapeutics
VRDN
51 hedge funds and large institutions have $60M invested in Viridian Therapeutics in 2017 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 7 closing their positions.
217% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 6
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
30% more capital invested
Capital invested by funds: $46.1M → $60M (+$13.9M)
16% more funds holding
Funds holding: 44 → 51 (+7)
0.15% more ownership
Funds ownership: 1.57% → 1.72% (+0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.09M |
| 2 |
Renaissance Technologies
New York
|
+$697K |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$460K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$421K |
| 5 |
VF
Virtu Financial
New York
|
+$348K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$965K |
| 2 |
SG Americas Securities
New York
|
-$250K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$147K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$95K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$90K |
VRDN Hedge Fund Activity: Q4 2017 in Review
51 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2017, worth a combined $60M — up 30% from $46.1M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new VRDN positions and 7 closed out — a net gain of 7 holders — while 19 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.09M. The largest seller was University of Texas/Texas AM Investment Management Co (UTIMCO), exiting entirely with an estimated $965K sold.
- 51 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2017, up from 44 in Q3 2017.
- Funds reported $60M of Viridian Therapeutics stock for Q4 2017, up 30% quarter-over-quarter.
- 14 funds opened new Viridian Therapeutics positions in Q4 2017 and 7 closed out, a net change of +7 holders.
- The largest Viridian Therapeutics buyer in Q4 2017 was Vanguard Group, an estimated $3.09M added.
- The largest Viridian Therapeutics seller in Q4 2017 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $965K sold.
Based on aggregated 13F filings for Q4 2017.